CN101262880A - 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物 - Google Patents

在影响呼吸道的炎症病状中气道施用组织因子途径抑制物 Download PDF

Info

Publication number
CN101262880A
CN101262880A CNA2006800310726A CN200680031072A CN101262880A CN 101262880 A CN101262880 A CN 101262880A CN A2006800310726 A CNA2006800310726 A CN A2006800310726A CN 200680031072 A CN200680031072 A CN 200680031072A CN 101262880 A CN101262880 A CN 101262880A
Authority
CN
China
Prior art keywords
tfpi
factor pathway
pathway inhibitor
tissue factor
aforementioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800310726A
Other languages
English (en)
Chinese (zh)
Inventor
拉斯·O·厄滕格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drugrecure AS
Original Assignee
Drugrecure AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure AS filed Critical Drugrecure AS
Publication of CN101262880A publication Critical patent/CN101262880A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2006800310726A 2005-06-24 2006-06-23 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物 Pending CN101262880A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
US60/693,968 2005-06-24

Publications (1)

Publication Number Publication Date
CN101262880A true CN101262880A (zh) 2008-09-10

Family

ID=37570814

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006800310726A Pending CN101262880A (zh) 2005-06-24 2006-06-23 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物
CN2006800310622A Expired - Fee Related CN101262879B (zh) 2005-06-24 2006-06-23 在影响呼吸道的炎症病状中气道施用活化的蛋白c

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006800310622A Expired - Fee Related CN101262879B (zh) 2005-06-24 2006-06-23 在影响呼吸道的炎症病状中气道施用活化的蛋白c

Country Status (14)

Country Link
US (3) US8088728B2 (cg-RX-API-DMAC7.html)
EP (3) EP1898945B1 (cg-RX-API-DMAC7.html)
JP (3) JP2008543926A (cg-RX-API-DMAC7.html)
KR (2) KR20080071116A (cg-RX-API-DMAC7.html)
CN (2) CN101262880A (cg-RX-API-DMAC7.html)
AU (2) AU2006273696B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0613137A2 (cg-RX-API-DMAC7.html)
CA (2) CA2612597C (cg-RX-API-DMAC7.html)
DK (3) DK1896059T3 (cg-RX-API-DMAC7.html)
IL (2) IL188221A0 (cg-RX-API-DMAC7.html)
NO (2) NO20080434L (cg-RX-API-DMAC7.html)
RU (2) RU2496515C2 (cg-RX-API-DMAC7.html)
WO (3) WO2007012976A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA200800251B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789193A (zh) * 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512350A (ja) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
ATE321846T1 (de) * 1996-11-08 2006-04-15 Oklahoma Med Res Found Verwendung eines modifizierten protein-c
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
AU2001232736A1 (en) * 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
IL158615A0 (en) * 2001-05-02 2004-05-12 Novo Nordisk As Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
BR0213293A (pt) * 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
KR100674315B1 (ko) * 2002-02-08 2007-01-24 에스케이 주식회사 가열로 튜브 세척제 및 세척방법
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
ES2321297T3 (es) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular.
EP1609471A1 (en) * 2003-03-31 2005-12-28 Kyowa Hakko Kogyo Co., Ltd. Remedy and/or preventive for lung diseases
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
CA2582353A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789193A (zh) * 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法

Also Published As

Publication number Publication date
RU2008102655A (ru) 2009-07-27
EP1906994B1 (en) 2014-04-23
EP1896059B1 (en) 2012-12-19
US20100160218A1 (en) 2010-06-24
WO2006136962A2 (en) 2006-12-28
DK1898945T3 (da) 2013-03-25
JP2013151510A (ja) 2013-08-08
IL188220A0 (en) 2008-03-20
DK1906994T3 (da) 2014-07-21
NO20080434L (no) 2008-03-17
US8088728B2 (en) 2012-01-03
AU2006273696A1 (en) 2007-02-01
WO2006136962A3 (en) 2007-07-12
CA2612646C (en) 2015-11-24
WO2007012976A3 (en) 2007-07-12
CA2612597C (en) 2015-03-31
BRPI0613137A2 (pt) 2010-12-21
CA2612597A1 (en) 2007-02-01
WO2007012976A2 (en) 2007-02-01
BRPI0611710A2 (pt) 2011-12-20
NO20080433L (no) 2008-03-19
ZA200800255B (en) 2009-04-29
ZA200800251B (en) 2009-04-29
HK1114567A1 (en) 2008-11-07
DK1896059T3 (da) 2013-04-08
AU2006273696B2 (en) 2012-08-30
EP1898945A2 (en) 2008-03-19
WO2006136963A2 (en) 2006-12-28
IL188221A0 (en) 2008-03-20
EP1906994A2 (en) 2008-04-09
US20100297099A1 (en) 2010-11-25
RU2008102656A (ru) 2009-07-27
EP1898945B1 (en) 2012-12-19
AU2006260599A1 (en) 2006-12-28
EP1896059A2 (en) 2008-03-12
RU2496516C2 (ru) 2013-10-27
KR20080071116A (ko) 2008-08-01
US20100279925A1 (en) 2010-11-04
KR20080074085A (ko) 2008-08-12
WO2006136963A3 (en) 2007-07-12
JP2008543925A (ja) 2008-12-04
CA2612646A1 (en) 2006-12-28
RU2496515C2 (ru) 2013-10-27
CN101262879B (zh) 2013-04-10
JP2008543926A (ja) 2008-12-04
CN101262879A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
CA2641875C (en) Pulmonary delivery of alpha-1 proteinase inhibitor
JP6001151B2 (ja) 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
US10960062B2 (en) Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
JP2013151510A (ja) 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与
WO2023014680A1 (en) System and method of treating or preventing respiratory failure with aerosolized collagenase
HUP0304050A2 (hu) Módosított FVII az ARDS kezelésre
AU2005282065A1 (en) Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
JP2023521530A (ja) ウイルス性肺炎を治療する方法及び薬剤
HK1114567B (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio
MX2007016370A (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
CN106061495A (zh) 肺内炎症的减弱

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080910